Critical Path to TB Drug Regimens
The CPTR initiative is dedicated to delivering a safer, more efficacious, and faster-acting tuberculosis (TB) regimen by developing and promoting innovative regulatory science essential for supporting new combination drug development in collaboration with its partners across industry, academia, and government.
Impact StoryMore Impact Stories >>
Sep 1, 2018 Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis
Jun 1, 2018 Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study
Jun 1, 2018 Mycobacterial biomaterials and resources for researchers
Mar 14, 2018 Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin
Mar 8, 2018 Quantitative Approach for Cardiac Risk Assessment and Interpretation in Tuberculosis Drug Development